ArticleInternational journal of cardiology. Heart & vasculature2026
Prognostic impact of high-risk plaque morphology and impaired physiology in untreated non-culprit coronary lesions: a systematic review and meta-analysis.
Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Pathophysiology-Oriented Imaging Phenotype Framework for Nonobstructive Coronary Artery Disease.Journal of cardiovascular development and disease · 2026Article
- The Association of C-Reactive Protein-Triglyceride Glucose Index with Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The management of angiographically intermediate coronary lesions (AICLs) remains challenging. Although current guidelines recommend physiological assessment to guide treatment decisions, residual atherothrombotic risk related to vulnerable plaque morphology may persist in deferred non-culprit lesions (NCLs). We performed a systematic review and meta-analysis to evaluate the prognostic impact of high-risk plaque morphology and impaired physiology in untreated NCLs. Methods: A systematic search of PubMed, Embase, and Web of Science identified 10 studies that included both morphological (optical coherence tomography [OCT], intravascular ultrasound [IVUS], or near infrared spectroscopy) and physiological (fractional flow reserve [FFR], instantaneous wave-free ratio, quantitative flow ratio [QFR], Murray fractal law-based QFR, optical flow reserve, OCT-FFR, or IVUS-FFR) assessment in the same untreated AICLs. Overall, 4757 patients with 7662 untreated NCLs were stratified into four groups: reference, morphology-positive, functional-positive, and morpho-functional-positive. The primary endpoint was target vessel failure (TVF), defined as a composite of cardiac death, target-vessel myocardial infarction, and target-vessel revascularization. Hazard ratios (HRs) were pooled using random-effects models. Results: Compared with the reference group, TVF risk was increased in morphology-positive lesions (HR 2.94, 95% confidence interval [CI] 2.22-3.90) and functional-positive lesions (HR 3.59, 95% CI 1.56-8.24). The highest risk was observed in the morpho-functional-positive group. Indirect comparison showed no significant difference between morphology-positive and functional-positive lesions. Conclusions: High-risk plaque morphology and impaired physiology were independently associated with adverse outcomes in untreated NCLs, while their coexistence identified lesions at highest risk. An integrated morpho-functional assessment may improve risk stratification in multivessel coronary artery disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.